Suchergebnisse - "DAMIA, G"

PubPharm (202)

1

Correction to : Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

enthalten in: British journal of cancer | 2023

von Guffanti, F. | Alvisi, M. | Anastasia, A. | +12

ErratumFor: Br J Cancer. 2022 Jan;126(1):120-128. - PMID 34732853

2

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

enthalten in: British journal of cancer | 2022

von Guffanti, F. | Alvisi, M. | Anastasia, A. | +12

ErratumIn: Br J Cancer. 2023 Mar;128(7):1405. - PMID 36797359

3

Overcoming PARPi resistance : Preclinical and clinical evidence in ovarian cancer

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2021

von Chiappa, M. | Guffanti, F. | Bertoni, F. | +2

4

Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients

in: Cancer Management and Research | 2019

von Corli O | Damia G | Galli F | +2

5

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells

enthalten in: Combinatorial chemistry & high throughput screening | 2018

von Ricci, F. | Carrassa, L. | Christodoulou, M. | +24

6

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells

enthalten in: Combinatorial chemistry & high throughput screening | 2018

von Ricci, F. | Carrassa, L. | Christodoulou, M. | +24

7

Abstract OT1-01-05: PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer

enthalten in: Cancer research | 2017

von La Verde, N. | Moretti, A. | Damia, G. | +20

8

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer

enthalten in: Scientific reports | 2016

von Guffanti, F. | Fruscio, R. | Rulli, E. | +1

9

Histone demethylating agents as potential S-adenosyl-l-methionine-competitors

enthalten in: MedChemComm | 2016

von Navakauskienė, R. | Mori, M. | Christodoulou, M. | +8

10

340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models

enthalten in: The European journal of cancer / A | 2014

von Guffanti, F. | Chila, R. | Bello, E. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]